13. Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details

Clinical trials : 3,340 /  Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

  
1 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT05482542
(ClinicalTrials.gov)		January 1, 202312/7/2022Optimal Conditioning Regimen for Autologous Transplantation of Relapsing Remitting Multiple SclerosisOptimal Conditioning Regimen Protocol for Autologous Hematopoietic Stem Cell Transplantation of Relapsing Remitting Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingOther: Autologous hematopoietic stem cell transplantation;Drug: Cyclophosphamide/ATG;Drug: Cyclophosphamide/RituximabScripps HealthNULLRecruiting18 Years58 YearsAll200N/AUnited States